赛升药业(300485) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥121,785,926.26, a decrease of 43.59% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥55,137,130.17, representing a decline of 398.95% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,603,646.82, down 75.58% from the previous year[5]. - Basic and diluted earnings per share were both -¥0.11, a decrease of 375.00% year-on-year[5]. - The company's operating income for the first nine months of 2023 was ¥393,823,690.35, down 34.28% from the same period in 2022[9]. - The total operating revenue for the third quarter of 2023 was RMB 393,823,690.35, a decrease of 34.3% compared to RMB 599,234,034.97 in the same period last year[23]. - Net profit attributable to shareholders decreased from ¥252,622,872.25 to ¥196,525,841.12, a decline of about 22.2%[26]. - Total comprehensive income decreased from ¥253,797,441.83 to ¥194,363,988.68, a decline of about 23.4%[26]. - Basic and diluted earnings per share decreased from ¥0.52 to ¥0.41, a decrease of approximately 21.2%[26]. Cash Flow and Investments - The operating cash flow net amount was ¥36,005,868.38, a decrease of 60.06% compared to the same period last year[5]. - Cash flow from operating activities decreased by 60.06% to CNY 36,005,868.38, mainly due to reduced sales and income[11]. - Cash flow from operating activities decreased from ¥637,304,775.12 to ¥446,833,275.74, a decline of about 30%[27]. - Cash flow from investing activities showed a net outflow of ¥19,880,505.52, compared to a larger outflow of ¥54,256,838.81 in the previous period[28]. - Cash flow from financing activities resulted in a net outflow of ¥41,395,507.03, compared to a net outflow of ¥80,308,316.53 in the previous period[28]. - The net cash flow from investing activities improved by 63.36% to CNY -19,880,505.52, primarily due to a decrease in principal amounts of financial investments[11]. - The company received cash from operating activities totaling ¥446,833,275.74, down from ¥637,304,775.12 in the previous period[27]. - The net increase in cash and cash equivalents for the period was -$24,536,957.37, compared to -$41,962,316.56 in the previous period[30]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥3,704,229,018.50, an increase of 3.79% from the end of the previous year[5]. - The company's cash and cash equivalents at the end of the period increased by 68.65% to CNY 201,673,605.50, attributed to a reduction in financial investments[11]. - The company's cash and cash equivalents decreased to RMB 201,673,605.50 from RMB 226,210,562.87 at the beginning of the year, representing a decline of 10.8%[20]. - The total liabilities decreased to RMB 139,273,108.85 from RMB 157,095,362.89, reflecting a reduction of 11.4%[22]. - The company's equity attributable to shareholders rose to RMB 3,530,108,525.78 from RMB 3,373,900,684.89, marking an increase of 4.6%[22]. - The deferred income tax liabilities rose to RMB 100,869,059.07 from RMB 82,159,469.58, an increase of 22.8%[22]. Research and Development - Research and development expenses for the first nine months were ¥54,287,924.94, a decrease of 31.76% year-on-year[9]. - Research and development expenses decreased from ¥79,555,905.38 to ¥54,287,924.94, a reduction of approximately 31.7%[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,565, with no preferred shareholders[13]. - The largest shareholder holds 49.51% of the shares, amounting to 238,464,000 shares[13]. - The company distributed dividends totaling CNY 41,395,507.03, a decrease of 48.82% compared to the previous period[11]. Other Information - The company reported a significant decrease in government subsidies received, totaling ¥200,844.31 for the first nine months, down 96.66% from the previous year[9]. - Cash received from tax refunds increased significantly by 5204.83% to CNY 12,545,695.91, primarily due to higher tax refunds received this period[11]. - The impact of exchange rate fluctuations on cash and cash equivalents was a decrease of 70.17%, mainly due to foreign exchange gains and losses from the Hong Kong subsidiary[11]. - The company acquired a 4.35% stake in Baixius for RMB 15,000,000, aligning with its strategic development direction[16]. - The subsidiary Junyuan Pharmaceutical received a production license for several drugs, enhancing the company's product portfolio[15]. - The third quarter report was not audited[31]. - The company implemented new accounting standards starting in 2023, affecting the financial statements[31].